Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niopeg
- Development stage
- Unknown
- Lead developer
- Sunshine Biopharma
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Niopeg is a biosimilar of pegfilgrastim, a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF), or filgrastim. It is designed to stimulate the production and maturation of neutrophils by binding to the G-CSF receptor on hematopoietic cells. This action reduces the incidence of infection as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs such as chemotherapy. Niopeg is administered via subcutaneous injection and is available in pre-filled syringes containing 6 mg/0.6 mL solution[1][2][3][9]. The drug was developed and commercialized by Nora Pharma (a division of Sunshine Biopharma) and received Health Canada approval in April 2024 as a biosimilar to Neulasta (pegfilgrastim)[1][2][3].
- Brand names
- NIOPEG
- Other names
- pegfilgrastim biosimilarpegylated filgrastimlong-acting recombinant human granulocyte colony-stimulating factorr-HuG-CSF biosimilar
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on niopeg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niopeg.